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Fig. S4. GPR40 has no effect on PPR for NMDA-mediated EPSCs. (A and B)
Representative traces of the PPR for NMDA-mediated EPSCs and summary of the PPR among the groups. For the analysis, n=6 in each group. The effect of each treatment was normalized to the baseline; error bars represent the mean ± s.e.m.; n.s., not significant, paired t-test. The summarized result of the spine density (DMSO n=24, GW9508 n=23, GW1100 n=21, one-way ANOVA followed by Tukey's test, ***p < 0.001). 
